Compare Sana Biotechnology Inc (SANA) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs UnitedHealth Group Inc — how do they compare? Sana Biotechnology Inc trades at $3.74 (market cap $1.13B), while UnitedHealth Group Inc trades at $405.47 (market cap $361.00B). The key difference: UnitedHealth Group Inc is far larger — about 319.5× Sana Biotechnology Inc's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | UNH | |
|---|---|---|
Market Cap | $1.13B | $361.00B |
Sector | Health | Health |
52-Week High | $5.92 | $436.35 |
52-Week Low | $2.68 | $259.02 |
Enterprise Value | $1.05B | $402.86B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
UnitedHealth Group (UNH) trades at $402.19, down 1.6% with bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats with Q1 2026 EPS of $7.23 beating estimates by 12%. Revenue grew to $447.57 billion in 2025, though net margins compressed to 2.69%. Analyst consensus remains strongly bullish with 83% buy ratings and a $476.50 price target representing 18% upside potential.
UNH presents a compelling long-term investment opportunity driven by aging demographics and healthcare digitization, but faces near-term headwinds from regulatory scrutiny and margin pressure. The stock's current valuation at 25.85x P/E appears reasonable given growth prospects, though investors should monitor legal challenges and Medicare reimbursement trends that could impact profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
